A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine

Messali, Serena; Bertelli, Anna; Campisi, Giovanni; Zani, Alberto; Ciccozzi, Massimo; Caruso, Arnaldo; Caccuri, Francesca

doi:10.1002/jmv.27247

Cited by 48 publications

(36 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas for the last mutations there are a plenty of data the information for the R346K substitution is limited. An initial study tested the effectiveness of sera collected from recipients of the BioNTech-Pfizer vaccine against the Mu variant and found that neutralization of SARS-CoV-2 B.1.621 lineage was robust, albeit at a lower level than that observed against the B.1 variant [3]. However, a recent study demonstrated that the Mu variant is highly resistant to sera from COVID-19 convalescents and BNT162b2-vaccinated individuals [4].…”

Section: Introductionmentioning

confidence: 99%

The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study

Fratev

2021

Preprint

View full text Add to dashboard Cite

The Mu variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the world health organization (WHO) but limited data are available at the moment. In particular, a special attention was given to the R346K mutation located in the receptor binding domain (RBD). In the current study we performed Free energy of perturbation (FEP) calculations to elucidate it possible impact on a set of neutralizing monoclonal antibodies (mAbs) which have been shown to be strong inhibitors of the most other known COVID-19 variants. Our results show that R346K affects the class 2 antibodies but its effect is not so significant (0.66 kcal/mol); i.e. reduces the binding with RBD about 3 times. An identical value was calculated also in the presence of both class 1 and class 2 antibodies (BD-812/836). Further, a similar reduction in the binding (0.4 kcal/mol) was obtained for BD-821/771 pair of mAbs. For comparison, the addition of K417N mutation, present in the newly registered Mu variant in July 2021 in UK, affected the class 1 mAbs by 1.29 kcal/mol reducing stronger the binding by about 10 times. Thus, the resistance effect of R346K mutation in the Mu variant is possible but not so significant and is due to the additional decrease of antibody neutralization based on the reduced binding of class 2 antibodies.

show abstract

Section: Introductionmentioning

confidence: 99%

The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study

Fratev

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The emergence of variants including the delta (B.1.617.2) and omicron (B.1.1.529) variants have already begun to raise questions about the efficacy rates of current COVID-19 vaccines [ 17 •• , 18 , 19 , 20 •• ]. It has been shown that the neutralizing activity of vaccine-induced antibodies is reduced against variants including the delta, beta (B.1.351), gamma (P.1), kappa (B.1.617.1) and mu (B.1.621) variants [ 21 , 22 , 23 , 24 , 25 ]. Compounding this scenario is the fact that herd immunity has not been, and may never be, reached by a combination of vaccination and natural infection due to a multitude of factors including limitations on vaccine availability around the globe, the fact that high vaccine efficacy rates are benchmarked against preventing severe disease not infection/transmission, vaccine hesitations/concerns and preexisting medical conditions.…”

Section: Approved Sars-cov-2 Vaccine Platformsmentioning

confidence: 99%

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines

Pelletier¹,

Sékaly

Tomalka

2022

Current Opinion in Virology

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls into question how effective current SARS-CoV-2 vaccines will be moving forward. Improving on vaccine platforms represents an opportunity to stay ahead of SARS-CoV-2 and keep the human population protected. Many researchers focus on modifying delivery platforms or altering the antigen(s) presented to improve the efficacy of the vaccines. Identifying mechanisms of natural immunity that result in the control of infection and prevent poor clinical outcomes provides an alternative approach to the development of efficacious vaccines. Early and current evidence shows that SARS-CoV-2 infection is marked by potent lung inflammation and relatively diminished antiviral signaling which leads to impaired immune recognition and viral clearance, essentially making SARS-CoV-2 ‘too hot to handle’.

show abstract

“…Although the global prevalence of the Mu variation among sequenced cases has decreased to below 0.1 percent, the prevalence in Colombia (39 percent) and Ecuador (40 percent) is still high (13 percent) Despite a few transformations in spike ,SARS-COV-2B.1.621 is neautarzalized by the P zer vaccine elicited antibodies, They note that the balance ,in spite of the fact successful ,was lower than that of the other corona virus variations (17).Snell et al ,proposes that MU variation has two cases of potential vaccine -espcape" .They categorized in that a few of the spike changes inside Mu 'have been detilaled to appear dimished balance by antibidoes .…”

Section: Mu: B1621 Lineagementioning

confidence: 99%

New Unknown Sars-Cov-2 Virus Variants and Hidden Pandemics Within Them in Developing Countries

Ghasemi

Dashti

2021

Preprint

View full text Add to dashboard Cite

It is not known whether one or a combination of different mutations will alter the viral clinical and epidemiological manifestations, transmissibility, virulence, or efficacy of the vaccine. Transmission of the new variant by asymptomatic carriers is also unknown. Vaccines or antiviral agents have not yet induced the pressure of the mutation; however, other mutations are anticipated after global vaccination and after the introduction of proven therapies. Thus, a willingness to rapidly emerge new options is prudent. Less virulent but highly heritable variants can also be expected, which may contribute to herd immunity. There is a need to develop clinical and rapid laboratory tests to monitor vaccinated individuals for secondary infection potentially caused by the new variant. Importantly, restrictive countermeasures, spatial distancing, personal hygiene, travel bans, and facial disguises remain relevant in the fight against the virus.

show abstract

A cluster of the new SARS‐CoV‐2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine

Cited by 48 publications

References 3 publications

The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study

The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines

New Unknown Sars-Cov-2 Virus Variants and Hidden Pandemics Within Them in Developing Countries

Contact Info

Product

Resources

About